Summary
Independence Blue Cross MA08.177a policy for Imetelstat (Rytelo®) was updated effective 06/29/2026. The policy deleted coverage criteria for patients with del(5q) disease and revised coverage criteria for patients without del(5q) disease, narrowing the eligible population for this MDS treatment. Billing teams must verify patient cytogenetic status and treatment history against updated NCCN-aligned criteria before processing claims.
Get alerts when payers change rules like this one
We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.
Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.
What to do
Action · 6 steps
01By 06/29/2026: Billing team must update prior authorization protocols and claim submission workflows for HCPCS code J0870 (Imetelstat injection).
02Update authorization request templates to require documentation of: (1) MDS diagnosis confirmed by bone marrow aspirate/biopsy, (2) patient cytogenetic status confirming absence of del(5q), (3) transfusion dependency (≥4 RBC units over 8 weeks, pretransfusion hemoglobin ≤9.0 g/dL), (4) IPSS-R score confirming low-to-intermediate risk disease, (5) ring sideroblast percentage, and (6) documented prior treatment failure/relapse with specific ESA, luspatercept-aamt, lenalidomide, or G-CSF regimens per policy criteria.
03Remove any authorization templates that previously included del(5q) patients.
04Train billing and authorization staff that del(5q) patients are NO LONGER covered under this policy.
05Claims submitted without complete cytogenetic documentation or from ineligible patient populations will be denied.
06Coordinate with providers to ensure clinical documentation supports all updated medical necessity criteria before submission.
Codes mentioned
J0870
Original notice
MA08.177a, Imetelstat (Rytelo®)
medpolicy.ibx.com · Always check the source before changing claims.